By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Investment firm RW Baird today initiated coverage of BG Medicine with an "Outperform" rating and a target price of $12 per share.

In a research note, analyst Quintin Lai wrote that the Waltham, Mass.-based developer of protein marker tests has demonstrated progress in its business, securing clearance with the US Food and Drug Administration in November for its Galectin-3 test for heart failure. Laboratory Corporation of America markets the test in the US.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Ancient DNA indicates Stone Age, hunter-gather inhabitants of Britain imported wheat.

Joel Achenbach explores at National Geographic why people find science difficult to believe.

In Science this week: gene linked to expansion of the human neocortex, and more.

The National Institute of General Medical Sciences director says changes the agency made have allow it to boost success rates.